USANA Health Sciences Inc
Stock Watch
Stock Watch will tell you what changes at USANA Health Sciences Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 12.90 $ to 23.20 $ · Last price: 14.30 $ (As of: October 30, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 10/30/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Packaged Foods
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| USANA Health Sciences Inc USNA | 0.3 | 30.3 | 2.6 | 77.5 | – | 8.3 | -26.9 |
| JBS N.V. JBS | 41.2 | 12.0 | 6.0 | 11.8 | 2.5 | 13.0 | 0.9 |
| Kraft Heinz Co KHC | 28.6 | – | 13.1 | 33.5 | 20.7 | -3.5 | 5.8 |
| General Mills Inc GIS | 18.6 | 8.8 | 20.8 | 33.7 | 19.2 | -1.9 | -22.1 |
| The J. M. Smucker Company SJM | 13.4 | – | 15.5 | 38.0 | 18.5 | 3.7 | 29.9 |
| McCormick & Company Incorporated MKC | 12.8 | 8.7 | 13.4 | 38.9 | 17.4 | 1.7 | -24.0 |
| McCormick & Company Incorporated MKC-V | 12.6 | 7.8 | 13.0 | 38.9 | 17.4 | 1.7 | -23.6 |
| Hormel Foods Corporation HRL | 11.9 | 28.9 | 15.6 | 15.7 | 11.1 | 1.6 | 2.7 |
| Darling Ingredients Inc DAR | 8.9 | 40.7 | 8.6 | 26.3 | 8.1 | 7.4 | 64.8 |
| Median of companies shown | 12.8 | 12.0 | 13.1 | 33.7 | 17.4 | 1.7 | 0.9 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 1,006 | 139 | 100 | 3.99 | 137 | 325 | 471 |
| 2017 | 1,047 | 133 | 63 | 2.53 | 124 | 363 | 519 |
| 2018 | 1,189 | 188 | 126 | 5.12 | 152 | 391 | 554 |
| 2019 | 1,061 | 146 | 101 | 4.41 | 127 | 352 | 517 |
| 2020 | 1,135 | 176 | 125 | 5.86 | 160 | 442 | 641 |
| 2021 | 1,186 | 170 | 117 | 5.73 | 121 | 395 | 578 |
| 2022 | 999 | 108 | 69 | 3.59 | 104 | 434 | 597 |
| 2023 | 921 | 93 | 64 | 3.30 | 71 | 497 | 633 |
| 2024 | 855 | 66 | 42 | 2.19 | 61 | 532 | 748 |
| 2025 | 925 | 51 | 11 | 0.58 | 22 | 533 | 743 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.23 | -73.00 | 214 | -3.40 | 2.10 | 6 | 4 |
| 2025: Q1 | 0.49 | -42.50 | 250 | 9.50 | 3.80 | 16 | 13 |
| 2025: Q2 | 0.52 | -4.30 | 236 | 10.80 | 4.10 | 12 | 7 |
| 2025: Q3 | -0.36 | -164.10 | 214 | 6.70 | -3.10 | -2 | -5 |
| 2025: Q4 | -0.10 | -141.30 | 226 | 5.90 | -0.80 | -3 | -6 |
| 2026: Q1 | 0.41 | -17.10 | 250 | 0.30 | 3.00 | 10 | 7 |
| 2026: Q2 | -1.16 | -323.10 | 223 | -5.30 | -9.60 | 23 | 20 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 4 of our scanner strategies — each hit links to the scanner.
Quality & Balance Sheet
Momentum & Trend
Value & GARP
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0.76 | 0.76 – 0.76 | 909 | -60.6% | 1 |
| 12/31/2027 | 1.77 | 1.77 – 1.77 | 945 | 132.9% | 1 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Instead of guessing what the stock is worth, we turn the question around: what free cash flow growth has to happen for today’s market value to add up? The assumptions behind it can be moved.
Today’s market value implies roughly 5.1% growth in free cash flow per year over ten years (assumptions: discount rate 10.0%, terminal growth 2.5%).
| Free cash flow (last twelve months) | $15.9M |
|---|---|
| Market cap | $264.0M |
| Free cash flow in year ten | $26.3M |
| Terminal value as a share of market value | 52.5% |
For comparison: over the past five years free cash flow shrank by 43.3% per year.
It shows which assumption is built into today’s price, not whether that assumption will hold. Every assumption can be changed with the sliders; the figures move with them.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -2.5%
- More than 10% revenue growth is expected for the coming year 6.0%
- Share count grows by less than 3% a year -1.3%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 9.2%
- Gross margin at 40% or higher and without meaningful erosion 78.3%
- Goodwill from acquisitions does not grow faster than revenue 18.6%
- Net debt below twice EBITDA 144 m net cash
- Operating cash flow covers the profits of the last three years 37 m
- Return on capital at 15% or higher, or up versus two years ago 8.3%
- Insiders hold at least 10% or are net buyers 40.9%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
4/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% -0.9%
- Exp. sales growth 3Y > 5% 1.1%
- EBIT growth 10Y > 5% -10.5%
- Exp. EBIT growth 3Y > 5% 74.8%
- Net debt < 4x EBIT -2.8x
- EBIT positive, 10Y straight 10
- Max. EBIT decline < 50% 73.0%
- Return on equity > 15% 4.1%
- ROCE > 15% 8.3%
- Expected return > 10% 80.4%
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
Insiders
Insider Transactions
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Oct 22, 2026 | Ding Xia | Director | Other | 604 | 14.52 | 8,770 |
| Oct 22, 2026 | Ding Xia | Director | Other | 1,632 | – | – |
| Oct 22, 2026 | Fleming John Turman | Director | Other | 1,632 | – | – |
| Oct 22, 2026 | Pelosi Peggie | Director | Other | 935 | 14.52 | 13,576 |
| Oct 22, 2026 | Pelosi Peggie | Director | Other | 1,632 | – | – |
| Oct 22, 2026 | Nixon J Scott | Director | Other | 1,632 | – | – |
| Oct 22, 2026 | Winssinger Frederic J | Director | Other | 1,632 | – | – |
| Oct 22, 2026 | Wood Timothy E | Director | Other | 408 | 14.52 | 5,924 |
| Oct 22, 2026 | Wood Timothy E | Director | Other | 1,632 | – | – |
| Oct 22, 2026 | Fuller Gilbert A | Director | Other | 1,632 | – | – |
The company
About the Company
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe.
- Employees
- 1,570
- Headquarters
- Salt Lake City, UT
- Address
- 3838 West Parkway Boulevard, 84120 Salt Lake City, United States
- Phone
- 801 954 7100
- Website
- usana.com
- IPO Date
- 07/25/1996
- ISIN
- US90328M1071
- Stock Split
- 2:1 on 11/23/2016
- Stock Split
- 2:1 on 10/31/2003
- Stock Split
- 2:1 on 08/04/1998
Management
| Name | Title | Birth Year |
|---|---|---|
| Kevin G. Guest | CEO & Executive Chairman | 1963 |
| G. Douglas Hekking | Chief Financial Officer | 1970 |
| Walter Noot | Chief Operating Officer | 1966 |
| P. Joshua Foukas J.D. | Chief Legal Officer, General Counsel & Corporate Secretary | 1976 |
| Brent L. Neidig | Chief Commercial Officer | 1984 |
| Myron W. Wentz Ph.D. | Founder & Chairman Emeritus | 1941 |
| John Cuomo | Executive Director of Product Development & Technology | – |
| Peter Benedict | Chief Information Officer | – |
| Kathryn Armstrong Ph.D. | Chief Scientific Officer | 1981 |
| Patrique Richards | Executive Director of Investor Relations & Business Development | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
- 10/05/2026 USANA HEALTH SCIENCES INC (USNA): Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; Financial Statements and Exhibits SEC ↗
- 08/04/2026 USANA HEALTH SCIENCES INC (USNA): Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Exhibits SEC ↗
Data as of: October 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.